Opportunity Information: Apply for RFA HD 14 031
Apply for RFA HD 14 031
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (SBIR) (R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Nov 7, 2013 and posted on Nov 7, 2013.
- Applicants must submit their applications by Feb 27, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,500,000.00 to eligible and selected applicants.
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This grant opportunity, titled "Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (SBIR) (R43/R44)" (Funding Opportunity Number RFA-HD-14-031), was a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) funding announcement aimed at pushing early-stage and follow-on development of therapeutics specifically intended for use during pregnancy. The central goal was to motivate small businesses to identify and validate molecular targets involved in pregnancy-associated or pregnancy-induced disorders, and then translate those discoveries into safer and more effective medications that could prevent or treat these conditions without creating unacceptable risks to the mother or fetus. In practical terms, the FOA was focused on moving beyond basic observation of pregnancy complications and instead zeroing in on actionable biology that could support drug discovery and therapeutic development.
The opportunity fell under NIH's health-related funding activities (CFDA 93.865, Child Health and Human Development Extramural Research) and was administered as a discretionary grant program. It used the SBIR R43/R44 mechanism, which typically corresponds to a phased innovation pathway: Phase I (R43) supports feasibility and proof-of-concept work, while Phase II (R44) supports more advanced research and development steps needed to bring a candidate therapeutic closer to clinical readiness. The structure signaled that NIH wanted projects with a clear translational trajectory, meaning applicants were expected to show not only that a molecular target mattered biologically, but also that it could realistically be leveraged to produce a therapeutic intervention suitable for pregnancy, where safety constraints, dosing considerations, and fetal exposure issues are especially stringent.
Eligibility was limited to small businesses, consistent with SBIR requirements. Foreign (non-U.S.) entities were not eligible to apply, and non-U.S. components of U.S. organizations were also not eligible. However, "foreign components" as defined under the NIH Grants Policy Statement could be allowable in some cases, which generally means that a U.S.-based small business could potentially include certain project elements conducted abroad if they met NIH policy requirements and were well-justified scientifically. No cost sharing or matching was required, which lowered the barrier for small businesses to propose ambitious early-stage R and D without needing to secure parallel non-federal funding as a condition of award.
From a funding standpoint, the estimated total funding amount listed for the announcement was $1,500,000. The FOA was posted on November 7, 2013, and it had an original and final closing date of February 27, 2014. The archive date was March 30, 2014, indicating the opportunity is no longer active and is retained for historical reference. For applicants at the time, this kind of timeline implied a single submission window rather than an open, recurring solicitation, so proposals needed to be prepared and submitted within that defined period.
Overall, the announcement reflected NIH interest in closing a long-standing gap in maternal-fetal medicine: many conditions that arise in pregnancy have limited treatment options, and many existing drugs lack robust evidence or acceptable safety profiles for pregnant patients. By emphasizing molecular target discovery paired with therapeutic development, the FOA was essentially asking small businesses to bridge the space between mechanistic insights and tangible interventions, with the explicit intent of delivering medications that could be used more confidently during pregnancy. The NIH provided an online link to the full announcement for details, and contact support was routed through the NIH Office of Extramural Research (OER) webmaster for access or linking issues.
Frequently Asked Questions (FAQs)
What is the name and funding opportunity number for this grant?
The opportunity is titled "Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (SBIR) (R43/R44)." The Funding Opportunity Number is RFA-HD-14-031.
Which agency offered this funding opportunity?
This was a National Institutes of Health (NIH) funding announcement under the Small Business Innovation Research (SBIR) program.
What is the main goal of this grant opportunity?
The central goal was to motivate small businesses to identify and validate molecular targets involved in pregnancy-associated or pregnancy-induced disorders and translate those discoveries into therapeutics intended for use during pregnancy. The emphasis was on developing safer and more effective medications to prevent or treat these conditions without unacceptable risk to the mother or fetus.
What types of projects was NIH trying to encourage through this FOA?
The FOA encouraged projects that move beyond observation of pregnancy complications and focus on actionable biology (molecular targets) that can support drug discovery and therapeutic development specifically appropriate for pregnancy, where safety constraints and fetal exposure considerations are especially stringent.
What funding mechanism was used (R43/R44), and what do the phases mean?
The FOA used the SBIR R43/R44 mechanism. Phase I (R43) generally supports feasibility and proof-of-concept work. Phase II (R44) generally supports more advanced research and development steps to move a candidate therapeutic closer to clinical readiness.
What does NIH mean by a "clear translational trajectory" in this context?
Applicants were expected to show not only that a molecular target was biologically relevant to a pregnancy-related/induced disease, but also that it could realistically be leveraged to produce a therapeutic intervention suitable for pregnancy, including consideration of safety constraints, dosing, and fetal exposure issues.
Who was eligible to apply?
Eligibility was limited to small businesses, consistent with SBIR requirements.
Were foreign (non-U.S.) entities eligible to apply?
No. Foreign (non-U.S.) entities were not eligible to apply.
Could non-U.S. components of U.S. organizations participate?
No. Non-U.S. components of U.S. organizations were not eligible.
Are any foreign components allowed at all?
In some cases, "foreign components" as defined under the NIH Grants Policy Statement could be allowable. This generally means a U.S.-based small business could potentially include certain project elements conducted abroad if they met NIH policy requirements and were well-justified scientifically.
Was cost sharing or matching required?
No cost sharing or matching was required.
How much total funding was estimated for this announcement?
The estimated total funding amount listed for the announcement was $1,500,000.
What CFDA program area did this opportunity fall under?
The opportunity was under CFDA 93.865, Child Health and Human Development Extramural Research.
What type of grant program was this considered?
It was administered as a discretionary grant program under NIH health-related funding activities.
When was the funding opportunity posted?
The FOA was posted on November 7, 2013.
What were the opening and closing dates for applications?
The FOA had an original and final closing date of February 27, 2014.
Is this opportunity still active?
No. The archive date was March 30, 2014, indicating the opportunity is no longer active and is retained for historical reference.
Did this FOA have multiple submission cycles or a single submission window?
Based on the listed original and final closing date, it implied a single submission window rather than an open, recurring solicitation, meaning proposals needed to be prepared and submitted within the defined period.
What problem area in maternal-fetal medicine was this FOA trying to address?
The announcement reflected NIH interest in closing a gap in maternal-fetal medicine: many conditions that arise in pregnancy have limited treatment options, and many existing drugs lack robust evidence or acceptable safety profiles for pregnant patients.
What kind of end result was NIH aiming for?
The FOA emphasized bridging mechanistic insights and tangible interventions, with the intent of delivering medications that could be used more confidently during pregnancy.
Where were applicants directed for details or access issues?
NIH provided an online link to the full announcement for details. Contact support for access or linking issues was routed through the NIH Office of Extramural Research (OER) webmaster.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01)
Previous opportunity: Museums, Libraries, and Cultural Organizations
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HD 14 031
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HD 14 031) also looked into and applied for these:
| Funding Opportunity |
|---|
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01) Apply for PAR 13 389 Funding Number: PAR 13 389 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (STTR) (R41/R42) Apply for RFA HD 14 032 Funding Number: RFA HD 14 032 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Centers for Collaborative Research in Fragile X (U54) Apply for RFA HD 14 033 Funding Number: RFA HD 14 033 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,300,000 |
| Juvenile Protective Factors and Their Effects on Aging (R03) Apply for PAR 14 022 Funding Number: PAR 14 022 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| U.S South Africa Program for Collaborative Biomedical Research (U01) Apply for RFA AI 14 018 Funding Number: RFA AI 14 018 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $225,000 |
| Data Sharing for Demographic Research Infrastructure Program (U24) Apply for RFA HD 14 015 Funding Number: RFA HD 14 015 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Intellectual and Developmental Disabilities Research Centers 2014 (U54) Apply for RFA HD 14 012 Funding Number: RFA HD 14 012 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,300,000 |
| Population Dynamics Centers Research Infrastructure (P2C) Apply for RFA HD 14 016 Funding Number: RFA HD 14 016 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Data Coordinating Center for the Collaborative Pediatric Critical Care Research Network (U01) Apply for RFA HD 14 020 Funding Number: RFA HD 14 020 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Collaborative Pediatric Critical Care Research Network (UG1) Apply for RFA HD 14 022 Funding Number: RFA HD 14 022 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Sustained Release for Antiretroviral Treatment or Prevention (SRATP) of HIV Infection (UM1) Apply for RFA AI 14 008 Funding Number: RFA AI 14 008 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Isolation, Purification, and Synthesis of Human Milk Oligosaccharides with Antimicrobial Activity (R43) Apply for RFA HD 15 008 Funding Number: RFA HD 15 008 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Isolation, Purification, and Synthesis of Human Milk Oligosaccharides with Antimicrobial Activity (R41) Apply for RFA HD 15 007 Funding Number: RFA HD 15 007 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Male Contraceptive Development Program (U01) Apply for RFA HD 14 034 Funding Number: RFA HD 14 034 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Global Omics Approaches Targeting Adverse Pregnancy and Neonatal Outcomes Utilizing Existing Cohorts (R01) Apply for PAR 14 264 Funding Number: PAR 14 264 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Peripheral Blood Biomarkers of Chronic Traumatic Brain Injury in Human Subjects SBIR Direct Phase II (R44) Apply for RFA HD 15 012 Funding Number: RFA HD 15 012 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $750,000 |
| Innovative Therapies and Tools for Screenable Disorders in Newborns (R21) Apply for PAR 14 269 Funding Number: PAR 14 269 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Innovative Therapies and Tools for Screenable Disorders in Newborns (R03) Apply for PAR 14 271 Funding Number: PAR 14 271 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Pharmacogenetics, Pharmacoepigenetics and Personalized Medicine in Children (R01) Apply for PAR 14 274 Funding Number: PAR 14 274 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Medically Assisted Reproduction Investigation of Mechanisms Underlying the Adverse Outcomes and Development of New and Improved Methods to Overcome the Adverse Outcomes (R01) Apply for PAR 14 272 Funding Number: PAR 14 272 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HD 14 031", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.